Analysts Anticipate Eagle Pharmaceuticals Inc (EGRX) Will Post Quarterly Sales of $51.15 Million
Wall Street brokerages expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to announce sales of $51.15 million for the current quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The highest sales estimate is $52.40 million and the lowest is $49.90 million. Eagle Pharmaceuticals reported sales of $46.79 million during the same quarter last year, which would suggest a positive year over year growth rate of 9.3%. The business is scheduled to announce its next quarterly earnings results on Monday, February 25th.
On average, analysts expect that Eagle Pharmaceuticals will report full year sales of $208.40 million for the current fiscal year, with estimates ranging from $207.20 million to $209.60 million. For the next financial year, analysts expect that the firm will post sales of $235.15 million, with estimates ranging from $219.80 million to $250.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.27. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. The business had revenue of $51.34 million during the quarter, compared to analysts’ expectations of $52.70 million. During the same quarter in the prior year, the company earned $1.22 EPS. The firm’s quarterly revenue was down 18.5% on a year-over-year basis.
EGRX opened at $50.61 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.59 and a quick ratio of 5.38. Eagle Pharmaceuticals has a 12 month low of $46.88 and a 12 month high of $85.66. The firm has a market capitalization of $774.74 million, a P/E ratio of 15.02 and a beta of 1.72.
A number of hedge funds and other institutional investors have recently made changes to their positions in EGRX. Wells Fargo & Company MN boosted its stake in Eagle Pharmaceuticals by 14.4% in the 1st quarter. Wells Fargo & Company MN now owns 23,287 shares of the specialty pharmaceutical company’s stock worth $1,228,000 after purchasing an additional 2,936 shares during the period. Russell Investments Group Ltd. boosted its stake in Eagle Pharmaceuticals by 563.5% in the 1st quarter. Russell Investments Group Ltd. now owns 5,779 shares of the specialty pharmaceutical company’s stock worth $304,000 after purchasing an additional 4,908 shares during the period. UBS Group AG boosted its stake in Eagle Pharmaceuticals by 362.1% in the 1st quarter. UBS Group AG now owns 47,980 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after purchasing an additional 37,597 shares during the period. Principal Financial Group Inc. boosted its stake in Eagle Pharmaceuticals by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 73,885 shares of the specialty pharmaceutical company’s stock worth $3,893,000 after purchasing an additional 2,436 shares during the period. Finally, Louisiana State Employees Retirement System acquired a new position in Eagle Pharmaceuticals in the 2nd quarter worth $280,000. 97.91% of the stock is owned by hedge funds and other institutional investors.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Recommended Story: Conference Calls and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.